ULTI_1170x120_3-2-21

Rupert Vessey

Bristol Myers Squibb to acquire Forbius

Bristol Myers Squibb to acquire Forbius

NEW YORK — Bristol Myers Squibb  and Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases, announced Monday that they have entered into a definitive agreement under which Bristol Myers Squibb will acquire Forbius. Forbius has developed a portfolio of highly selective and potent